Genmab

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Employees: 2.2K

Market Cap: $17.7B

Website: http://www.genmab.com

Clinical Trials

A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors

Phase 1

Terminated

Conditions: Prostate Cancer
Triple Negative Breast Cancer (TNBC)
Uterine Cancer
Squamous Cell Carcinoma of Head and Neck (SCCHN)
Non-small Cell Lung Cancer (NSCLC)
Bladder Cancer
Esophageal Cancer
Locally Advanced or Metastatic Solid Tumor(s)

Interventions: Biological: GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.

First Posted Date: 2020-06-11

Last Posted Date: 2023-07-25

Lead Sponsor: Genmab

Target Recruit Count: 48

Registration Number: NCT04424641

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Tennesse Oncology, PLLC - Nashville, Nashville, Tennessee, United States
🇩🇰
Rigshospitalet (Copenhagen University Hospital), Copenhagen, Denmark

and more 3 locations

First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Phase 1

Terminated

Conditions: Follicular Lymphoma
Marginal Zone Lymphoma
Mantle Cell Lymphoma
Primary Mediastinal Large B-cell Lymphoma
Chronic Lymphocytic Leukemia
Diffuse Large B-cell Lymphoma
Small Lymphocytic Lymphoma
High-grade B-cell Lymphoma

Interventions: Biological: GEN3009
Biological: Epcoritamab

First Posted Date: 2020-04-24

Last Posted Date: 2024-10-24

Lead Sponsor: Genmab

Target Recruit Count: 46

Registration Number: NCT04358458

Locations: 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
🇺🇸
Ohio State University, Columbus, Ohio, United States

and more 14 locations

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

Phase 1

Recruiting

Conditions: Malignant Solid Tumor
Non-Small Cell Lung Cancer (NSCLC)
Colorectal Cancer (CRC)
Melanoma
Head and Neck Squamous Cell Carcinoma (HNSCC)
Pancreatic Ductal Adenocarcinoma (PDAC)

Interventions: Biological: GEN1042
Drug: Pembrolizumab
Drug: Cisplatin
Drug: Carboplatin
Drug: 5-FU
Drug: Gemcitabine
Drug: Nab paclitaxel
Drug: Pemetrexed
Drug: Paclitaxel

First Posted Date: 2019-09-10

Last Posted Date: 2024-12-03

Lead Sponsor: Genmab

Target Recruit Count: 1287

Registration Number: NCT04083599

Locations: 🇺🇸
Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States
🇺🇸
Cancer & Blood Specialty Clinic, Los Alamitos, California, United States
🇺🇸
Moores Cancer Center at the UC San Diego Health, San Diego, California, United States

and more 72 locations

GEN1046 Safety Trial in Patients With Malignant Solid Tumors

Phase 1

Active, not recruiting

Conditions: Urothelial Carcinoma
Solid Tumors
Squamous Cell Carcinoma of the Head and Neck
Non-small Cell Lung Cancer
Triple Negative Breast Cancer
Cervical Cancer
Endometrial Carcinoma

Interventions: Biological: Acasunlimab
Biological: Acasunlimab in combination with docetaxel (in a single expansion cohort)
Biological: Acasunlimab in combination with pembrolizumab (in a separate expansion cohort)
Biological: Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts)

First Posted Date: 2019-04-17

Last Posted Date: 2024-12-03

Lead Sponsor: Genmab

Target Recruit Count: 429

Registration Number: NCT03917381

Locations: 🇬🇪
LTD Consilium Medulla, Tbilisi, Georgia
🇪🇸
IOB-Hospital Quironsalud Barcelona, Barcelona, Spain
🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Spain

and more 52 locations

A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Drug: tisotumab vedotin

First Posted Date: 2019-04-12

Last Posted Date: 2022-06-23

Lead Sponsor: Genmab

Target Recruit Count: 23

Registration Number: NCT03913741

Locations: 🇯🇵
National Cancer Center Hospital, Chuo-ku, Tokyo-To, Japan
🇯🇵
Keio University Hospital, Shinjuku-ku, Tokyo-To, Japan
🇯🇵
NHO Shikoku Cancer Center, Matsuyama-Shi, Ehime-Ken, Japan

and more 5 locations

First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma

Phase 1

Active, not recruiting

Conditions: Primary Mediastinal Large B-cell Lymphoma (PMBCL)
FL
Small Lymphocytic Lymphoma (SLL)
DLBCL
High-grade B-cell Lymphoma (HGBCL)
MCL
Marginal Zone Lymphoma (MZL)

Interventions: Biological: Epcoritamab

First Posted Date: 2018-08-10

Last Posted Date: 2024-12-03

Lead Sponsor: Genmab

Target Recruit Count: 666

Registration Number: NCT03625037

Locations: 🇫🇮
Helsinki University Hospital, Helsinki, Finland
🇺🇸
University of California at San Francisco, San Francisco, California, United States
🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

and more 82 locations

GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors

Phase 1

Terminated

Conditions: Gastric Cancer
Urothelial Cancer
Colorectal Cancer
Non-small Cell Lung Cancer
Renal Cell Carcinoma
Pancreatic Cancer
Triple Negative Breast Cancer

Interventions: Biological: GEN1029 (HexaBody®-DR5/DR5)

First Posted Date: 2018-07-03

Last Posted Date: 2023-08-01

Lead Sponsor: Genmab

Target Recruit Count: 48

Registration Number: NCT03576131

Locations: 🇺🇸
UT M.D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Yale University, New Haven, Connecticut, United States
🇪🇸
Hospital Univeritario Vall d'Hebron, Barcelona, Spain

and more 3 locations

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

Phase 1

Completed

Conditions: Cervical Cancer
Endometrial Cancer
Thyroid Cancer
Melanoma
Sarcoma
Ovarian Cancer
Non Small Cell Lung Cancer (NSCLC)
Solid Tumors

Interventions: Biological: Enapotamab vedotin (HuMax-AXL-ADC)

First Posted Date: 2016-12-09

Last Posted Date: 2023-08-01

Lead Sponsor: Genmab

Target Recruit Count: 306

Registration Number: NCT02988817

Locations: 🇬🇧
The Royal Marsden Hospital, Sutton, United Kingdom
🇧🇪
CHU de Liège, Medical Oncology et. Domaine Universitaire du Sart Tilman, Liege, Belgium
🇳🇱
Erasmus MC, Medical Oncology, Rotterdam, Netherlands

and more 38 locations

Zalutumumab in Non-Small Cell Lung Cancer (NSCLC) Patients Refractory to Tyrosine Kinase Inhibitors

Phase 2

Withdrawn

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: zalutumumab

First Posted Date: 2011-10-10

Last Posted Date: 2011-10-10

Lead Sponsor: Genmab

Registration Number: NCT01449357

Zalutumumab Pharmacokinetics (PK) in Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Phase 1

Completed

Conditions: Head and Neck Cancer

Interventions: Biological: zalutumumab

First Posted Date: 2010-01-22

Last Posted Date: 2023-08-03

Lead Sponsor: Genmab

Target Recruit Count: 31

Registration Number: NCT01054625

Locations: 🇸🇰
FN Tnava, Trnava, Slovakia
🇧🇪
Cliniques Universitaires SaintLuc, Brussels, Belgium
🇭🇺
Vas Megye es Szombathely, Szombathely, Hungary

and more 4 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy